Scarica l'app Stockscreener
21.95
35.36%
5.685
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.26
Aprire:
$22.8
Volume 24 ore:
15.80M
Relative Volume:
16.84
Capitalizzazione di mercato:
$496.10M
Reddito:
$59,000
Utile/perdita netta:
$-78.26M
Rapporto P/E:
-3.5997
EPS:
-6.0964
Flusso di cassa netto:
$-51.46M
1 W Prestazione:
+66.74%
1M Prestazione:
+35.28%
6M Prestazione:
+42.74%
1 anno Prestazione:
+360.46%
Intervallo 1D:
$17.69
$23.71
Intervallo di 1 settimana:
$12.55
$23.71
Portata 52W:
$3.39
$23.71
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
21.77 | 370.54M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-04-06 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Citizens raises Avalo Therapeutics stock price target on trial data - Investing.com
Avalo Therapeutics Prices $375 Million Public Offering; Shares Up Pre-Bell - marketscreener.com
Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why - Benzinga
Avalo Therapeutics Announces $375 Million Public Offering Priced May 6, 2026 - geneonline.com
Avalo Therapeutics prices $375 million stock offering By Investing.com - Investing.com Australia
Avalo Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Avalo prices $375M sale to fund drug development through Phase 3 data - Stock Titan
Avalo Therapeutics announces pricing of $375 million public offering at $17.75 per share - marketscreener.com
Avalo Therapeutics Announces Pricing of $375 Million Public Offering - GlobeNewswire
Avalo Therapeutics Reports Strong Phase 2 Hidradenitis Data - TipRanks
Avalo’s abdakibart meets primary endpoint in hidradenitis trial By Investing.com - Investing.com Australia
Avalo Therapeutics launches public stock offering By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) prospectus: stock and pre-funded warrants offering with Phase 2 data - Stock Titan
Avalo Therapeutics stock surges 35% on positive trial data - Investing.com
Avalo Therapeutics launches public stock offering - Investing.com
Avalo launches stock sale to fund Phase 3 abdakibart work - Stock Titan
Avalo's skin disease drug beat placebo in Phase 2, heads to Phase 3 - Stock Titan
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa - The Manila Times
Strong Phase 2 HS data for abdakibart boosts Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
Avalo Therapeutics Achieves Positive Topline Results in - GlobeNewswire
This Avalo Therapeutics analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
Jennison Associates LLC Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock - MarketBeat
Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock - MarketBeat
Avalo Therapeutics (AVTX) CFO trims stake in 10b5-1 share sales - Stock Titan
Insider sale of 16,915 restricted shares (AVTX) - Stock Titan
Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform By Investing.com - Investing.com Australia
Moody Aldrich Partners LLC Buys Shares of 133,231 Avalo Therapeutics, Inc. $AVTX - MarketBeat
Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform - Investing.com
AVTX Q1'26 Earnings: EPS estimate is (1.18) USD - TradingView
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics (AVTX) Secures Milestone Buyout Option with A - GuruFocus
Avalo Therapeutics enters milestone buyout option agreement on April 26SEC filing - marketscreener.com
Avalo Therapeutics Restructures AlmataBio Milestone Payment Obligations - TipRanks
Avalo Therapeutics Purchases Optional Milestone Buyout - The Manila Times
Avalo Therapeutics (NASDAQ: AVTX) adopts optional milestone buyout structure - Stock Titan
Avalo pays $2.25M for 90-day option to replace $15M payout - Stock Titan
Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Avalo Therapeutics (AVTX) - The Globe and Mail
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Avalo (AVTX) Stock: Buy, Sell, Hold? (Smart Money Outflows) 2026-04-15Trend Signals - Cổng thông tin điện tử tỉnh Lào Cai
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Increase in Short Interest - MarketBeat
AVTX Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Short Squeeze: Can Avalo Therapeutics Inc grow without external funding2026 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Breakout Move: Is Avalo Therapeutics Inc a potential multi baggerWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Avalo Therapeutics (NASDAQ: AVTX) sets 2026 virtual meeting and ESPP changes - Stock Titan
Death Cross: Will Avalo Therapeutics Inc be affected by tariffsWeekly Loss Report & Daily Profit Focused Screening - baoquankhu1.vn
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
AVTX: Wolfe Research Initiates Coverage with 'Outperform' Rating - GuruFocus
Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48 - Moomoo
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):